Silence Therapeutics PLC
silence-therapeutics.comWhat Do They Do?
Develops small interfering RNA medicines designed to silence disease-related genes for patients with rare and common diseases.
10-K for FY2025, filed Mar 5, 2026We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or…View ↗
Divesiran (SLN124) is our potential first-in-class siRNA in Phase 2 development for polycythemia vera, or PV. PV is a rare…View ↗
Zerlasiran (SLN360) is our Phase 3 ready siRNA product candidate for cardiovascular disease that works by "silencing" the LPA gene…View ↗
Who Are Their Customers?
AstraZeneca and Hansoh work with Silence through research collaboration agreements to develop RNA-based medicines; Silence also receives royalty income.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
Partnering its cardiovascular candidate
The earlier report described the cardiovascular candidate as wholly owned; the latest says Silence is seeking an outside partner to advance and potentially commercialize zerlasiran.
20-F for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 5, 2026SLN360, an siRNA targeting the LPA gene, is our wholly owned product candidate currently in phase 2 clinical development (ALPACAR-360…View ↗
Zerlasiran (SLN360) is our Phase 3 ready siRNA product candidate for cardiovascular disease that works by "silencing" the LPA gene…View ↗
Loading...
